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A phase 1 clinical trial was conducted among 35 healthy adult volunteers to evaluate the safety, immuno-
genicity, and shedding of different doses of CVD 1207, a live attenuated Shigella flexneri 2a vaccine candidate
with specific deletion mutations in virG, sen, set, and guaBA. CVD 1207 retains the ability to invade epithelial
cells but cannot effectively spread intercellularly after invasion (DvirG), does not produce enterotoxin (Dsen
and Dset), and has limited proliferation in vivo (DguaBA). In a consecutive fashion, groups of three to seven
subjects ingested a single oral dose of CVD 1207 at an inoculum of either 106, 107, 108, 109, or 1010 CFU. CVD
1207 was remarkably well-tolerated at inocula as high as 108 CFU. In comparison, one of 12 subjects who
received 109 CFU experienced mild diarrhea and another experienced a single episode of emesis. One of five
subjects who received 1010 CFU experienced watery diarrhea and emesis. All subjects who ingested doses of 108
to 1010 CFU excreted the vaccine; in 23 of 25, the duration of excretion was <3 days. A dose-related,
immunoglobulin A antibody-secreting cell (ASC) response to S. flexneri 2a O-specific lipopolysaccharide was
seen, with geometric mean peak values of 6.1 to 35.2 ASCs/106 peripheral blood mononuclear cells (PBMC)
among recipients of 107 to 1010 CFU. The cytokine response to Shigella-specific antigens observed in volunteers’
PBMC following vaccination suggested a Th1 pattern with stimulation of gamma interferon and absence of
interleukin 4 (IL-4) or IL-5. CVD 1207 represents a Shigella live oral vaccine strain prepared from wild-type
S. flexneri 2a by rational use of recombinant DNA technology that achieves a remarkable degree of attenuation
compared with earlier recombinant strains, even when administered at high dosage.
The number of Shigella episodes that occur throughout the
world each year is estimated to be 165 million, with more than
1 million of these illnesses resulting in death (19). In some
areas of the world, mortality among children 1 to 4 years old
attributed to dysentery exceeds mortality from watery diarrhea,
and Shigella is the most common etiologic agent associated
with dysentery (1). The increasing burden of shigellosis reflects
an inability of existing medical and public health measures to
diminish transmission adequately or to curtail the clinical con-
sequences of infection. Alternatively, prevention by the use of
a safe and effective vaccine offers great potential as a means of
diminishing the global disease burden from shigellosis.
One approach to the development of Shigella vaccines is to
attenuate wild-type strains by mutating genes that regulate
specific virulence properties. The aim is to construct a vaccine
that expresses critical antigens in their native form but cannot
induce undesirable pathological processes. To date, the gener-
ation of a live attenuated vaccine that elicits protective immu-
nity yet is safe and genetically stable has been problematic (6,
13, 18).
Here we report the safety, immunogenicity, and dose re-
sponse of CVD 1207, a DvirG Dsen Dset DguaBA Shigella flex-
neri 2a live attenuated vaccine candidate. CVD 1207, derived
from the wild-type strain 2457T (7), contains precise mutations
in the genes encoding either virulence factors or essential met-
abolic enzymes: (i) the plasmid gene virG (also known as icsA),
which encodes a protein responsible for cell-to-cell spread of
Shigella in the intestinal epithelium (2, 20); (ii) the chromo-
somal gene set encoding Shigella enterotoxin 1 (ShET1), which is
present almost exclusively in S. flexneri 2a (11); (iii) the plasmid
gene sen, encoding Shigella enterotoxin 2 (ShET2), which is
present in virtually all serotypes of Shigella (29); and (iv) the
guaBA chromosomal operon that regulates synthesis of IMP
dehydrogenase (encoded by guaB) and GMP synthetase (en-
coded by guaA), two enzymes employed in the distal de novo
purine biosynthesis pathway (32). CVD 1207 thus expresses
type-specific O-polysaccharide and invades epithelial cells (al-
beit less competently than the wild type) but undergoes only
limited intracellular proliferation and intercellular spread and
has no detectable enterotoxic activity.
MATERIALS AND METHODS
Construction of CVD 1207. CVD 1207 was constructed from wild-type S.
flexneri 2a strain 2457T by a series of double homologous recombinations using
suicide plasmid deletion cassette technology as described in detail elsewhere
(31). In brief, a specific, in-frame deletion mutation in the guaBA operon was first
introduced, followed by a second in-frame deletion mutation in the plasmid
virulence gene virG (32). The chromosomal mutation Dset was accomplished with
deletion of 85% of subunit A of set (31). Finally, a Dsen cassette was constructed
by fusing two 700-bp segments that include the N and C termini of sen minus 300
bp corresponding to the putative active site in the N-terminal region. The ars
operon, conferring resistance to arsenite, was cloned into the Dsen locus to allow
facile transfer of the double-deletion mutation (DvirG and Dsen) virulence plas-
mid to candidate Shigella vaccine strains and as a marker to distinguish CVD
1207 in the field (31).
As previously described, CVD 1207 does not grow in minimum medium unless
supplemented with guanine (31). The lack of enterotoxic activity has been con-
firmed in Ussing chambers (31). CVD 1207 is significantly less invasive for HeLa
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cells than its wild-type parent strain 2457T (approximately 1 log unit fewer
intracellular CFU detected) but does not differ from its single-mutant strain
progenitor DguaBA CVD 1204 (unpublished observations). CVD 1207 under-
goes fewer intracellular generations in HeLa cells (7.5-fold; 3 doublings in 4 h)
than either CVD 1204 (10-fold; 4.5 doublings in 4 h) or 2457T (30-fold; 5
doublings in 4 h) (unpublished observations). In the guinea pig purulent kera-
toconjunctivitis (Serény) model, CVD 1207 is fully attenuated (evokes no in-
flammatory response) and confers 85% protection against challenge with the
wild-type parent strain (31).
Preparation of challenge inoculum. The vaccine inocula were prepared from
frozen master seed stocks (to guarantee clonal continuity), which were plated
onto Trypticase soy agar (TSA; Becton Dickinson, Cockeysville, Md.) containing
0.01% Congo red dye (Sigma Chemical Co., St. Louis, Mo.) and 0.005% guanine
(Sigma). After incubation at 35°C for 18 to 24 h, single, isolated Congo red-
positive colonies that exhibited characteristic Shigella morphology were con-
firmed as S. flexneri 2a by using specific antisera (Difco Laboratories, Detroit, Mich.).
Several well-isolated Congo red-positive colonies were picked and suspended in
sterile saline. The saline suspension was then used to inoculate (for heavy
growth) guanine-supplemented TSA plates, which were incubated overnight at
35°C. Overnight growth from the TSA plates was then harvested into sterile
phosphate-buffered saline, pH 7.4, and washed three times. The heavy bacterial
suspension was diluted with additional sterile phosphate-buffered saline to pro-
duce a suspension with an optical density at 660 nm corresponding to the desired
bacterial count per milliliter. Replicate colony counts performed before and after
vaccination were averaged to estimate the actual inoculum of vaccine ingested.
Subject selection. Adult volunteers 18 to 55 years of age, recruited from the
University of Maryland Baltimore campus, underwent a battery of clinical and
laboratory screening tests to ensure that they were healthy and comprehended
the study protocol. Subjects were excluded if they were employed as food han-
dlers, shared a household with an immunocompromised person or a child
younger than 5 years of age, had previous exposure to Shigella (in the form of a
vaccine or a known history of wild-type infection), or had received antibiotic
therapy during the 7 days before inoculation. As a precaution, volunteers who
tested positive for HLA B27 were excluded from participating because this
haplotype is rarely associated with reactive arthritis following infection with
certain strains of Shigella which bear a 2-MDa plasmid not contained in CVD
1207 (14, 43). Informed, written consent was obtained according to the guide-
lines of the Institutional Review Board of the University of Maryland, Baltimore.
Study design. Groups of 3 to 7 outpatient volunteers were assigned, in an
incremental fashion, to receive a single oral dose of CVD 1207 at a desired
inoculum (the actual inocula administered are in parentheses) of either 106
(1.2 3 106), 107 (1.9 3 107), 108 (1.7 3 108), 109 (8.9 3 108, 2.1 3 109, or 4.1 3
109), or 1010 (7.8 3 109 or 2.1 3 1010) CFU (Table 1). Fasting volunteers
swallowed the vaccine suspended in a solution of NaHCO3 buffer, as previously
described (15).
For 14 days after vaccination, the volunteers telephoned or visited the center
to report the occurrence of symptoms, their evening oral temperatures, the total
number of formed and loose stools passed, and the presence of blood in the
stool. Adverse clinical responses occurring within 7 days of inoculation were
considered possibly vaccine related and are reported here. Volunteers who
developed clinical symptoms or prolonged shedding could receive ciprofloxacin
(500 mg) by mouth twice daily for 5 days at the investigator’s discretion.
Bacteriology. Fecal excretion of the vaccine strain in the volunteer’s stools was
measured on days 1, 2, 3, 7, 10, 14, and 21 after ingestion of the vaccine. To
obtain a stool specimen, volunteers swabbed the perirectal area immediately
after defecation and placed the swab in a vial containing buffered glycerol saline
(47). The swab was maintained in an insulated bag cooled with an ice pack until
delivery to the laboratory within 24 h of passage (47). Volunteers provided a
rectal swab (inoculated into gram-negative broth [Becton Dickinson]) at the
study site if a perirectal specimen was not collected at home. Swabs were culti-
vated on Salmonella-Shigella and MacConkey’s enteric media (Becton Dickin-
son). Lactose-negative colonies identified after 24 or 48 h of incubation at 35°C
on solid medium were inoculated onto triple sugar iron slants (Difco Laborato-
ries). Those producing an alkaline slant and an acid butt with no gas were verified
as S. flexneri by demonstrating agglutination with group B polyclonal antiserum
(Difco Laboratories). All media were supplemented with 0.01% guanine (Sigma).
ASC responses. Peripheral blood mononuclear cells (PBMC) were collected
before and on days 7 and 10 after vaccination to measure circulating immuno-
globulin A (IgA) antibody-secreting cells (ASC) recognizing O-specific lipopoly-
saccharide (LPS) antigen of S. flexneri 2a (45), as an indication of intestinal
priming induced by vaccination. A positive ELISPOT response was defined as a
postvaccination count per 106 PBMC of $3 standard deviations above the mean
prevaccination count (in the log metric); one volunteer who had a prevaccination
ASC count of 20 was excluded from this analysis.
Serum antibody responses. Sera were collected before and 14, 21, 28, and 42
days after immunization and evaluated by enzyme-linked immunosorbent assay
(ELISA) for IgA and IgG antibodies to the O-specific LPS antigen of S. flexneri
2a (3) and the invasiveness plasmid antigens using published methods (35, 46).
Seroconversion was defined as a fourfold or greater rise in titer.
Cell-mediated immune responses. (i) Isolation of PBMC. PBMC from volun-
teers drawn before and 28 to 45 days after immunization were isolated and either
cryopreserved in 10% dimethyl sulfoxide (Sigma) in liquid N2 as described
previously (44) or used immediately. No significant differences were observed in
the proliferative responses of freshly obtained or cryopreserved PBMC in re-
sponse to either tetanus toxoid (TT) or phytohemagglutinin (PHA) stimulation.
(ii) Bacterial antigen preparations. A DaroA mutant strain of S. flexneri 2a
(CVD 1201) (33) was used as a source of homogenate and particulate Shigella
antigens. Particulate Shigella consisted of a heat-phenolized preparation (46).
Bacterial homogenate was prepared as described previously (39), except that a
whole-bacterial pellet was used rather than a periplasmic extraction and the
100,000 3 g ultracentrifugation step was not performed. The Bacillus subtilis
control strain (Ehrenberg) Cohn, ATCC 7067, was obtained from the American
Type Culture Collection (Manassas, Va.). Purified recombinant S. flexneri IpaC
and IpaD invasins were prepared as previously described (23, 37).
(iii) Incubation of PBMC with antigens. Frozen PBMC were quickly thawed,
resuspended in complete medium, washed (44), and resuspended in AIM-V
medium (Gibco BRL, Grand Island, N.Y.) at a density of 1.5 3 106/ml. The
antigens were prepared in AIM-V medium and then added to achieve the
following final concentrations: S. flexneri 2a homogenate, 1, 2, 10, or 25 mg/ml;
S. flexneri 2a particulate, 5 3 104, 2 3 105, or 8 3 105 particles (CFU of
heat-phenolized whole-cell bacteria)/well; IpaC, 2, 6, or 12 mg/ml; IpaD, 2, 6, or
12 mg/ml; B. subtilis homogenate, 1, 2, 10, or 25 mg/ml; B. subtilis particulate, 5 3
104, 2 3 105, or 8 3 105 particles/well; TT (Connaught Laboratories, Toronto,
Canada), 2 mg/ml; PHA, 1.8 mg/ml; and bovine serum albumin (Sigma), 10 or 25
TABLE 1. Clinical and immunological responses to live attenuated vaccines derived from S. flexneri 2a strain 2457T and




No. (%) of subjects with: Anti-LPS IgA ASC
Diarrhea Fever Dysentery No. (%) respondersb Geometric mean
CVD 1207 106 7 0 0 0 0 0.1
107 7 0 0 0 6 (100)c 6.1
108 3 0 0 0 2 (67) 5.3
109 12d 1 (8) 0 0 7 (64) 8.7
1010 6e 1 (20) f 0 0 5 (100)e 35.2
CVD 1203 (18) 106 10 0 0 0 6 (60) 13.0
108 11 2 (18) 1 (9) 1 (9) 10 (91) 43.0
109 11 3 (27) 7 (64) 3 (27) 11 (100) 175.0
Wild-type 2457T (17)g 102 7 3 (43) 2 (29) 3 (43) 5 (71) 18.4
103 12 10 (83) 10 (83) 10 (83) 11 (92) 239.0
a Volunteers were assigned to a dose group, for the purpose of assessing dose response, by rounding the inoculum received in 0.5-log-unit increments to the nearest
log value.
b Response was defined as a geometric mean postvaccination count per 106 PBMC of .2 standard deviations above the mean prevaccination count.
c Two subjects were excluded from the analysis of IgA anti-LPS responses. One recipient of 107 CFU had a prevaccination IgA anti-LPS ASC level of 20, and one
recipient of 1010 CFU had no blood sample for measurement of IgA anti-LPS ASC on day 10.
d One recipient of this inoculum vomited once.
e One subject was excluded from analysis of clinical symptoms because she developed an acute febrile respiratory influenza A illness.
f This subject also experienced three episodes of vomiting.
g Protective efficacy against shigellosis following rechallenge was 70%; P 5 0.003.
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mg/ml. For cytokine and proliferation assays, 7.5 3 105 cells and 1.5 3 105 PBMC
were added to 24-well (in duplicate) and 96-well (in triplicate) plates (Corning,
Corning, N.Y.), respectively. The plates were incubated at 37°C and 5% CO2 in
humidified chambers. The supernatants were collected after 3 days for determi-
nation of cytokine levels. Proliferation plates were pulsed with [3H]thymidine on
day 6 and harvested 18 h later.
(iv) Proliferation assays and cytokine analysis by chemiluminescence ELISA.
[3H]thymidine incorporation and measurement of cytokines by chemilumines-
cence ELISA were performed as described previously (36, 39, 43). The sensitiv-
ities of the ELISAs were as follows: interleukin 2 (IL-2), 13 pg/ml; IL-4, 23 pg/ml;
IL-5, 24 pg/ml; gamma interferon (IFN-g), 18 pg/ml; IL-10, 10 pg/ml; IL-12, 44
pg/ml; IL-15, 45 pg/ml; and transforming growth factor b (TGF-b), 11 pg/ml. No
cytokine production or proliferative response to control antigens was observed in
any volunteer.
Analytic methods. The frequency of adverse clinical responses during days 0 to
6 following vaccination was determined for each group of subjects, with day 0
beginning with vaccination. The primary outcome measures were fever (oral
temperature, $100.0°F), diarrhea (three or more loose stools within a 24-h
period), and dysentery (gross blood in a loose stool). The relationship between
dose and ASC count was analyzed by linear regression, using log-transformed
data. Volunteers were assigned to a dose group, for the purpose of assessing dose
response, by rounding the inoculum received in 0.5-log-unit increments to the
nearest log value.
For lymphocyte proliferative responses, the “net” (antigen-specific response
minus the PBMC in medium alone) counts per minute in triplicate wells of
PBMC from each subject before and after immunization, incubated with the
same concentration of the same antigen, were compared by paired two-tailed t
tests. For cytokine responses, duplicate chemiluminescence units before and
after immunization following PBMC exposure to the same concentration of the
same antigen were compared for each subject by paired two-tailed t tests. Re-
sponses were defined as occurring when statistical tests yielded a probability that
was #5%.
RESULTS
Clinical tolerance. CVD 1207 was well tolerated in doses
ranging from 106 to 108 CFU (Table 1). One subject, who
received 109 CFU, reported a single episode of emesis on day
2. A second subject, who received 109 CFU, experienced diar-
rhea, with passage of eight loose stools over 24 h. The diarrhea
began 24 h after inoculation, required no medical intervention,
and resolved spontaneously. One recipient of 1010 CFU passed
five loose stools and vomited three times during the first 24 to
36 h after inoculation. She was treated with ciprofloxacin and
recovered rapidly. No subject experienced fever or dysentery.
Bacteriologic response. The pattern of excretion was dose
related, such that all recipients of 108 or more CFU had pos-
itive stool cultures (Table 2). The duration of excretion was 1
to 3 days except for two recipients of ca. 109 CFU, who each
had one additional positive stool culture 2 weeks after vacci-
nation. Both subjects were treated with ciprofloxacin and had
three subsequent negative stool cultures.
ASC response. An anti-LPS IgA-producing ASC response
(.2 ASC per 106 PBMC) was detected in 64 to 100% of
subjects who ingested an inoculum of 107 CFU or higher (Ta-
ble 1). The geometric mean of the peak postvaccination re-
sponse ranged from 5.3 to 35.2 ASC count per 106 PBMC
among recipients of at least 107 CFU. As shown in Fig. 1, there
was a significant positive relationship between dose and num-
ber of IgA-producing anti-LPS ASC (linear regression of log-
transformed data; r 5 0.61; P 5 0.001).
Humoral immune response. The serologic response to vac-
cination was modest and was seen primarily at the higher
doses. Among 18 recipients of 109 or 1010 CFU, 3 (17%)
mounted a fourfold rise in IgG and 2 (11%) produced a four-
fold rise in IgA anti-LPS antibody. Vaccination elicited a four-
fold rise in anti-invasiveness plasmid antigen IgG antibody in
two subjects (11%) and IgA antibody in one subject (6%).
Cytokine production and proliferation responses by PBMC.
Among subjects in the 109-CFU dose group with evaluable
assays (i.e., strong proliferation in response to PHA and TT),
one had a proliferative response both to the S. flexneri 2a
homogenate and to IpaD (Table 3). This subject also produced
an IFN-g and IL-10 response to IpaD, both TGF-b and IL-10
responses to homogenate, and a TGF-b response IpaC. A sec-
ond volunteer mounted an IL-10 response to S. flexneri partic-
ulate. A third recipient of 109 CFU produced strong IFN-g
responses to S. flexneri homogenate and particulate prepara-
tions and an IL-10 response to IpaC.
One of the three individuals with evaluable assays in the
1010-CFU dose group had a strong proliferative response to S.
flexneri 2a particulate antigens and also proliferated in re-
sponse to IpaD (Table 3). This same volunteer, in addition to
one other subject, produced TGF-b in response to IpaD. No
increases in IL-4 or IL-5 levels produced by PBMC were noted
following immunization in either cohort.
DISCUSSION
Shigella is notorious for its ability to cause clinical disease
after ingestion of as few as 10 organisms (10). Indeed, when the
wild-type parent of CVD 1207, S. flexneri 2a strain 2457T, is
administered with bicarbonate buffer to volunteers, as little as
103 CFU consistently causes diarrhea and dysentery in 80 to
90% of the subjects (17). Previous attempts to attenuate viru-
lent S. flexneri 2a strain 2457T by engineering precise deletions
FIG. 1. Anti-LPS IgA ASC responses to oral inoculation with DguaBA DvirG
Dsen Dset S. flexneri 2a vaccine CVD 1207, by dose. The peak IgA anti-LPS ASC
response measured 7 or 10 days after vaccination for each volunteer is indicated
by a circle. There was a significant positive relationship between dose and peak
number of ASC enumerated (linear regression of log-transformed data; r 5 0.61;
P 5 0.001).
TABLE 2. Fecal excretion of Shigella CVD 1207 by dose group
Dose group
(CFU)a
No. (%) of subjects
with positive stool
culture/total
Mean no. of days with
positive stool culture
(range)b
106 1/7 (14) 1.0 (NAc)
107 2/7 (28) 1.5 (1–2)
108 3/3 (100) 2.0 (1–3)
109 12/12 (100) 5.9 (1–14)
1010 10/10 (100) 1.7 (1–3)
a Volunteers were assigned to a dose group, for the purpose of assessing dose
response, by rounding the inoculum received in 0.5-log-unit increments to the
nearest log value.
b This represents the number of days after vaccination that the last positive
stool culture was detected and includes only subjects found to be excreting the
vaccine for at least one day.
c NA, not applicable.
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of genes encoding virulence attributes met with only limited
success; at doses producing immune responses (108 or more
CFU), shigellosis-like adverse reactions (diarrhea, fever, and
dysentery) were observed in many vaccinees (18, 22). The
findings in this paper are noteworthy because they demon-
strate that the introduction of multiple rational mutations has
attenuated strain 2457T to a degree not previously achieved.
This generates optimism that it may indeed be possible to
prepare a safe and well-tolerated live, invasive vaccine strain
from a fully virulent strain of S. flexneri 2a using recombinant
techniques. Among the 35 subjects who ingested 106 to 1010
CFU of CVD 1207, adverse reactions were mild and occurred
only at the highest ($109 CFU) inocula. Furthermore, no
subject experienced fever or dysentery, generally the most un-
comfortable symptoms of shigellosis. Since a safety margin of
approximately 2 log units may be acceptable for a live vaccine
candidate, an inoculum of 107 CFU of CVD 1207 would be
appropriate for further testing. Since the 108-CFU dose group
contained only three subjects, additional evaluation of this
inoculum would further ensure that there is no significant
reactogenicity at this level.
CVD 1207 represents an important step in the considerable
clinical experience that has accrued with vaccines derived from
the virulent parent, S. flexneri 2a strain 2457T. Recently, prac-
tical progress has been made toward moving into clinical trial
another S. flexneri 2a candidate vaccine, SC602, a DvirG (icsA)
Diuc live oral vaccine derived from S. flexneri 2a strain 454.
While SC602 and CVD 1207 share a mutation in virG (icsA) as
an attenuating lesion, one cannot draw conclusions about the
attenuating effects of this mutation, since the two strains were
derived from different wild-type backgrounds and each vaccine
candidate possesses distinct additional mutations. Notably,
CVD 1207 is constructed from strain 2457T, whose virulence
has been repeatedly demonstrated in volunteers (15–17); to
our knowledge, the degree of virulence of the wild-type parent
of SC602 (strain 454) has not been assessed in volunteer stud-
ies.
By examining the clinical response to vaccine candidates
derived from S. flexneri 2a strain 2457T, one can begin to
elucidate the attenuating effect in humans of specific genetic
mutations, a process that is not possible when evaluating Shi-
gella vaccines that are constructed from different parent strains
or from parent strains with uncharacterized pathogenicities.
Lindberg and colleagues constructed SFL 1070 from S. flexneri
2a strain 2457T using a chromosomal mutation in aroD, which
encodes an enzyme in the aromatic amino acid biosynthesis
pathway that is necessary to sustain bacterial replication within
human cells (22). In volunteer trials, SFL 1070 was measurably
attenuated compared to the wild type but still induced residual
dose-related reactogenicity (gastrointestinal symptoms and fe-
ver) in 10 to 44% of the subjects who received three doses of
105 to 109 CFU (13). In an attempt to further attenuate S.
flexneri 2a strain 2457T, Noriega et al. constructed CVD 1203
by introducing a deletion in the plasmid gene virG (34), in
addition to a deletion in the chromosomal gene aroA (34).
CVD 1203 was highly immunogenic, with geometric mean IgA
anti-LPS ASC counts of 13, 43, and 175 per 106 PBMC fol-
lowing administration of inocula of 106, 108, and 109 CFU,
respectively (Table 1). However, whereas no adverse reactions
(diarrhea, dysentery, or fever) were observed in recipients of
106 CFU, unacceptable reactions were seen in 18% of subjects
who ingested 108 CFU and in 78% of those who ingested 109
CFU (Table 1) (18).
Noriega et al. next explored the attenuating effects of chro-
mosomal mutations affecting enzymes employed in the distal
purine biosynthesis pathway. First, they constructed CVD 1204
by introducing specific deletions in the guaBA operon (32).
When directly compared with a DaroA mutant strain, CVD
1204 was significantly less invasive in HeLa cells and induced
significantly less conjunctival inflammation in the guinea pig
keratoconjunctivitis (Serény) test (32). A double DguaBA
DvirG mutant, CVD 1205, elicited fewer inflamed eyes than did
CVD 1204 (5 out of 16 versus 11 out of 16), although this
difference was not statistically significant (32). It was hoped
that the diminished virulence in preclinical studies of S. flexneri
2a attenuated with DguaBA and DvirG would eliminate the
residual constitutional symptoms associated with DaroA DvirG
CVD 1203 in volunteers. Next, in an effort to minimize diar-
rheal reactogenicity, CVD 1207 was constructed, harboring
deletion mutations in the S. flexneri 2a enterotoxin genes sen
(29) and set (11), in addition to guaBA and virG. As expected,
CVD 1207 was markedly attenuated compared with previous
constructs (15, 18); it was completely devoid of reactions at 108
CFU and induced only mild gastrointestinal complaints, with-
out fever or dysentery, in 3 of 18 subjects (17%) inoculated
with 109 or 1010 CFU. The etiology of residual diarrhea at
higher doses remains elusive, since in vivo studies suggest that
enterotoxic activity is absent; one possible explanation is that
the vaccine strain elicited a local intestinal inflammatory re-
sponse, including the release of proinflammatory cytokines,
which manifested at the high inocula.
The significance of the modest serum antibody responses to
CVD 1207 (and other attenuated Shigella vaccine candidates)
is uncertain. Anti-LPS serum IgG is a response that has been
correlated (3, 4, 5) (albeit inconsistently [9; D. Cohen, M. S.
Green, C. Block, R. Slepon, and Y. Lerman, Letter, J. Infect. Dis.
TABLE 3. Peak proliferation and peak cytokine production by PBMC in response to various antigens after





Proliferation IL-2 IL-4 IL-5 IFN-g IL-10 IL-12 IL-15 TGF-b
109 CFU SF homogenate 1/7 0/8 0/4 0/4 1/8 1/8 0/3 0/3 1/1
SF particulate 0/7 0/8 0/4 0/4 1/8 1/8 0/3 0/3 0/1
IpaC 0/6 0/7 0/4 0/4 0/8 1/8 0/3 0/3 1/1
IpaD 1/6 0/7 0/4 0/4 1/8 1/8 0/4 0/4 0/1
1010 CFU SF homogenate 0/3 NDb 0/3 ND 0/3 0/3 ND ND 0/3
SF particulate 1/3 ND 0/3 ND 0/3 0/3 ND ND 0/3
IpaC 0/3 ND 0/3 ND 0/3 0/3 ND ND 0/3
IpaD 1/3 ND 0/3 ND 0/3 0/3 ND ND 2/3
a SF, S. flexneri.
b ND, not done.
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165:785–787, 1992]) with immunity to shigellosis. Although the
failure of CVD 1207 to induce a vigorous serologic response is
disappointing, there is ample precedent for inoculations which
elicit protective immunity evoking relatively weak serum anti-
body responses in clinical trials. For example, streptomycin-
dependent S. flexneri 2a vaccine (also derived from wild-type
strain 2457T) (28) induced a fourfold rise in anti-LPS hemag-
glutinating antibody in only 38% of subjects who received five
doses of 1010 CFU (8), a dosage level which confers 49%
protective immunity against experimental challenge (9), and
.85% protection against natural infection in field trials (24,
27). Similarly, experimental wild-type S. flexneri 2a challenge
induces serum anti-LPS IgG antibody responses in approxi-
mately 50% of subjects (16) yet confers 70% protection against
illness following rechallenge (17).
Anti-Shigella LPS ASC responses have also been correlated
with protective immunity in clinical trials (16). The geometric
mean IgA anti-LPS ASC response is approximately 239 per 106
PBMC following virulent infection (Table 1) (17) and 18 per
106 PBMC following vaccination with SC602, a DvirG Diuc live
oral vaccine derived from S. flexneri 2a strain 454 that con-
ferred protection against illness following experimental chal-
lenge (6). The magnitude of the IgA anti-LPS ASC response
that was elicited by CVD 1207 at well-tolerated dose levels (5.3
to 6.1 per 106 PBMC) falls short of these values. It is necessary
to conduct challenge studies to determine whether CVD 1207
can provide protective immunity.
Significant IFN-g, IL-10, and/or TGF-b responses to Shigel-
la-specific antigens were detected in five volunteers immunized
with CVD 1207. A similar (albeit more pronounced) cytokine
response was found in a recently completed study using PBMC
from volunteers exposed to a DstxA (i.e., non-Shiga toxin-pro-
ducing) wild-type Shigella dysenteriae type 1 strain (39). This
cytokine pattern, characteristic of a Th1 response—as indi-
cated by the production of IFN-g and the absence of IL-4 or
IL-5—is likely to play an important role in protection from
Shigella, an intracellular pathogen. IFN-g is produced by T
cells following antigen-specific stimulation, as well as by natu-
ral killer cells, and has the ability to stimulate macrophages to
kill phagocytosed microbes and to prevent Shigella invasion of
epithelial cells (30). While both TGF-b and IL-10 may be in-
volved in stimulating an antibody response, IL-10 in particular
may serve as a counterregulatory cytokine to the IFN-g re-
sponses induced by Shigella. Furthermore, IL-10 may inhibit
IL-1, a critical trigger of the strong intestinal inflammatory
response that occurs with shigellosis (41).
The relatively meager proliferative responses in this trial
(observed in 2 of 10 subjects who received 109 or 1010 CFU of
CVD 1207) and in the previous trial using virulent nontoxi-
genic S. dysenteriae type 1 (39), is consistent with the lack of
production of IL-2, IL-12, and IL-15, all of which promote
T-cell proliferation. However, these limited specific prolifera-
tive responses cannot necessarily be construed as an indication
that this attenuated Shigella vaccine strain is a poor immuno-
gen. Bacterial species may inhibit proliferation by triggering
IFN-g, IL-10, and TGF-b production and by using a variety of
independent mechanisms (38, 40). Some investigators have
suggested that Shigella subverts host defenses by inhibiting
macrophage presentation of Shigella antigens and possibly
even by inducing apoptosis of macrophages (12, 42).
It is noteworthy that specific cytokine and/or proliferation
responses to IpaC and IpaD were observed in 4 of 11 volun-
teers immunized with CVD 1207, suggesting that these pro-
teins are potentially important epitopes in the human host
immune response to shigellosis. These responses were specific,
since neither TT nor bovine serum albumin induced cytokine
responses nor were the responses attributable to contamina-
tion with LPS (data not shown). To our knowledge, this is the
first demonstration in humans that S. flexneri 2a vaccination
elicits cell-mediated immune responses to Shigella invasins.
Since these proteins are conserved among Shigella species, they
offer the potential for inducing cross-serotype protection.
In sum, we have demonstrated that CVD 1207 is highly
attenuated and well tolerated at dosage levels that were mark-
edly reactogenic with earlier invasive S. flexneri 2a vaccine
candidates. Moreover, when the occasional adverse reactions
did occur at very high dosage levels, neither fever nor dysen-
tery was encountered. The clinical response to CVD 1207
appears to be at least as acceptable as the responses to other S.
flexneri 2a vaccines that progressed to phase 2 evaluations, such
as the streptomycin-dependent strains (21, 25, 26), the Esche-
richia coli-S. flexneri 2a hybrid EcSf2a-2 (15), and SC602 (6).
Nonetheless, it is conceivable that at well-tolerated dosage
levels, CVD 1207 may be insufficiently immunogenic after a
single dose. Therefore, a strategy of administering two spaced
doses at inoculum levels that are clinically well tolerated may
be advisable to achieve an acceptable balance between reacto-
genicity and immunogenicity. It is possible that lyophilization
may temper the post-vaccination reactions without compro-
mising immunogenicity, as was the case with streptomycin-de-
pendent vaccines (24). Another consideration for future trials
is to evaluate other engineered S. flexneri 2a 2457T strains,
such as CVD 1204 (DguaBA) (32) and CVD 1208 (DguaBA
Dsen Dset), to assess their immunogenicities and reactogenici-
ties in relation to those of CVD 1207.
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